【摘要】 目的　通过研究卵巢肿瘤组织中钙黏素 (cadherin) 6基因的表达、突变及其临床意义 ,以寻找与卵巢肿瘤发生相关的分子水平标志物。方法　应用RT PCR技术和PCR 单链构象多态性方法分别检测恶性卵巢肿瘤组织 (4 1份 )、良性卵巢肿瘤组织 (15份 )、正常卵巢组织 (17份 )中cadherin 6mRNA的表达及cadherin 6基因的突变情况 ,并分析其临床意义。结果　正常卵巢组织、良性卵巢肿瘤组织、恶性卵巢肿瘤组织中cadherin 6mRNA阳性率分别为 71%、5 3%、2 4 % ,前两者显著高于后者 (P<0 0 5 )。cadherin 6mRNA阳性率与恶性卵巢肿瘤手术病理分期有关 ,Ⅲ～Ⅳ期恶性卵巢肿瘤组织中 ,cadherin 6mRNA阳性率 (5 % )显著低于Ⅰ～Ⅱ期 (4 5 % ,P <0 0 1)。 4 1例恶性卵巢肿瘤患者中 ,2例出现cadherin 6基因突变 ,而在正常卵巢组织和良性卵巢肿瘤组织中无cadherin 6基因突变。结论　cadherin 6mRNA在晚期恶性卵巢肿瘤组织中表达缺失。提示cadherin 6mRNA表达可作为判断恶性卵巢肿瘤预后的一个指标更多还原

【Abstract】 Objective To study expression and mutation of cadherin 6 gene in human ovarian tumor tissues and its clinical significance and to explore new molecular biomarker of ovarian tumors. Methods The expression and mutation of cadherin 6 in 41 cases of malignant ovarian tumors, 15 cases of benign ovarian tumors and borderline ovarian tumors and 17 cases of normal tissues were detected by RT-PCR and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique respectively. Results The positive expression rates of cadherin 6 were 71% in normal group, 53% in benign ovarian tumors, 24% in malignant ovarian tumors, being significantly higher in the former two groups than in malignant tumor group ( P<0.05) . Statistical analysis revealed a significant correlation between cadherin 6 gene expression and clinical stages and histological subtype of malignant ovarian tumors. Lower expression rate of cadherin 6 gene was found in cancer tissues at stages Ⅲ～Ⅳ than at stages Ⅰ～Ⅱ(P<0.01). No mutation was found in normal group and benign tumor tissues and it was observed in 2 out of 41 malignant ovarian tumor tissues. Conclusions These results suggest that expression of cadherin 6 gene tends to lack in advanced ovarian carcinoma with lymph node metastases, as well as in poorly differentiated carcinomas. It may be a prognostic marker of ovarian carcinoma.更多还原